{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:23:40Z","timestamp":1775143420375,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11010-024-05127-5","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T06:02:19Z","timestamp":1728712939000},"page":"2555-2571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-OAcGD2 antibody in combination with ceramide kinase inhibitor mediates potent antitumor cytotoxicity against breast cancer and diffuse intrinsic pontine glioma cells"],"prefix":"10.1007","volume":"480","author":[{"given":"Angelina","family":"Kasprowicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeyye","family":"Cavdarli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Delannoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Le Guezennec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Defebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corentin","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Jonckheere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Le Doussal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Ange","family":"Krzewinski-Recchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Meignan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Groux-Degroote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"key":"5127_CR1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cellimm.2018.03.007","volume":"333","author":"JG Rodrigues","year":"2018","unstructured":"Rodrigues JG et al (2018) Glycosylation in cancer: selected roles in tumour progression, immune modulation and metastasis. Cell Immunol 333:46\u201357","journal-title":"Cell Immunol"},{"key":"5127_CR2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1196\/annals.1377.017","volume":"1086","author":"K Furukawa","year":"2006","unstructured":"Furukawa K, Hamamura K, Aixinjueluo W, Furukawa K (2006) Biosignals modulated by tumor- associated carbohydrate antigens: novel targets for cancer therapy. Ann NY Acad Sci 1086:185\u2013198","journal-title":"Ann NY Acad Sci"},{"key":"5127_CR3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-015-0399-5","volume":"75","author":"S Dhillon","year":"2015","unstructured":"Dhillon S (2015) Dinutuximab: first global approval. Drugs 75:923\u2013927","journal-title":"Drugs"},{"key":"5127_CR4","doi-asserted-by":"crossref","first-page":"601076","DOI":"10.3389\/fonc.2020.601076","volume":"10","author":"T Blom","year":"2020","unstructured":"Blom T et al (2020) Treatment-related toxicities during anti-GD2 immunotherapy in high- risk neuroblastoma patients. Front Oncol 10:601076","journal-title":"Front Oncol"},{"key":"5127_CR5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40265-021-01467-4","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A (2021) Naxitamab: first approval. Drugs 81:291\u2013296","journal-title":"Drugs"},{"key":"5127_CR6","doi-asserted-by":"crossref","first-page":"e25220","DOI":"10.1371\/journal.pone.0025220","volume":"6","author":"N Alvarez-Rueda","year":"2011","unstructured":"Alvarez-Rueda N et al (2011) A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross- reactivity. PLoS ONE 6:e25220","journal-title":"PLoS ONE"},{"key":"5127_CR7","doi-asserted-by":"crossref","first-page":"e87210","DOI":"10.1371\/journal.pone.0087210","volume":"9","author":"M Terme","year":"2014","unstructured":"Terme M et al (2014) Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti- neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PLoS ONE 9:e87210","journal-title":"PLoS ONE"},{"key":"5127_CR8","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/cells10061468","volume":"10","author":"S Cavdarli","year":"2021","unstructured":"Cavdarli S et al (2021) Role of sialyl-O-acetyltransferase CASD1 on GD2 ganglioside O- acetylation in breast cancer cells. Cells 10:1468","journal-title":"Cells"},{"key":"5127_CR9","doi-asserted-by":"crossref","first-page":"E370","DOI":"10.3390\/ijms21010370","volume":"21","author":"S Cavdarli","year":"2020","unstructured":"Cavdarli S et al (2020) Profiling of O-acetylated gangliosides expressed in neuroectoderm derived cells. Int J Mol Sci 21:E370","journal-title":"Int J Mol Sci"},{"key":"5127_CR10","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1038\/s41598-020-61283-w","volume":"10","author":"P Bhadwal","year":"2020","unstructured":"Bhadwal P et al (2020) LC-HRMS based approach to identify novel sphingolipid biomarkers in breast cancer patients. Sci Rep 10:4668","journal-title":"Sci Rep"},{"key":"5127_CR11","doi-asserted-by":"crossref","first-page":"18239","DOI":"10.1038\/s41598-022-20976-0","volume":"12","author":"P Bhadwal","year":"2022","unstructured":"Bhadwal P, Randhawa V, Vaiphei K, Dahiya D, Agnihotri N (2022) Clinical relevance of CERK and SPHK1 in breast cancer and their association with metastasis and drug resistance. Sci Rep 12:18239","journal-title":"Sci Rep"},{"key":"5127_CR12","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/ijms21041396","volume":"21","author":"S Schwalm","year":"2020","unstructured":"Schwalm S et al (2020) Ceramide kinase is upregulated in metastatic breast cancer cells and contributes to migration and invasion by activation of PI 3-kinase and Akt. Int J Mol Sci 21:1396","journal-title":"Int J Mol Sci"},{"key":"5127_CR13","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.3390\/cancers14184496","volume":"14","author":"K Rajput","year":"2022","unstructured":"Rajput K et al (2022) Ceramide kinase (CERK) emerges as a common therapeutic target for triple positive and triple negative breast cancer cells. Cancers 14:4496","journal-title":"Cancers"},{"key":"5127_CR14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1515\/BC.2009.054","volume":"390","author":"A Cazet","year":"2009","unstructured":"Cazet A et al (2009) GD3 synthase overexpression enhances proliferation and migration of MDA-MB-231 breast cancer cells. Biol Chem 390:601\u2013609","journal-title":"Biol Chem"},{"key":"5127_CR15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.devcel.2011.06.014","volume":"21","author":"D Moreau","year":"2011","unstructured":"Moreau D et al (2011) Genome-wide RNAi screens identify genes required for Ricin and PE intoxications. Dev Cell 21:231\u2013244","journal-title":"Dev Cell"},{"key":"5127_CR16","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H et al (2019) Welcome to the tidyverse. J Open Source Softw 4:1686","journal-title":"J Open Source Softw"},{"key":"5127_CR17","doi-asserted-by":"crossref","first-page":"774846","DOI":"10.3389\/fgene.2021.774846","volume":"12","author":"S Xu","year":"2021","unstructured":"Xu S et al (2021) Use ggbreak to effectively utilize plotting space to deal with large datasets and outliers. Front Genet 12:774846","journal-title":"Front Genet"},{"key":"5127_CR18","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-98141-3","volume-title":"Ggplot2 elegant graphics for data analysis","author":"H Wickham","year":"2009","unstructured":"Wickham H (2009) Ggplot2 elegant graphics for data analysis, 2nd edn. Springer, Cham","edition":"2"},{"key":"5127_CR19","unstructured":"Slowikowski K, Schep A, Hughes S (2021) ggrepel: automatically position non-overlapping text labels with \u2018ggplot2\u2019 version from CRAN. https:\/\/rdrr.io\/cran\/ggrepel\/."},{"key":"5127_CR20","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie Z et al (2021) Gene set knowledge discovery with enrichr. Curr Protoc 1:e90","journal-title":"Curr Protoc"},{"key":"5127_CR21","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT- PCR. Nucleic Acids Res 29:e45","journal-title":"Nucleic Acids Res"},{"key":"5127_CR22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676\u2013682","journal-title":"Nat Methods"},{"key":"5127_CR23","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41592-019-0582-9","volume":"16","author":"S Berg","year":"2019","unstructured":"Berg S et al (2019) ilastik: interactive machine learning for (bio)image analysis. Nat Methods 16:1226\u20131232","journal-title":"Nat Methods"},{"key":"5127_CR24","doi-asserted-by":"crossref","first-page":"e74250","DOI":"10.1371\/journal.pone.0074250","volume":"8","author":"R Aguirre-Gamboa","year":"2013","unstructured":"Aguirre-Gamboa R et al (2013) SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS ONE 8:e74250","journal-title":"PLoS ONE"},{"key":"5127_CR25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/1471-2105-14-290","volume":"14","author":"P Kumar","year":"2013","unstructured":"Kumar P, Goh G, Wongphayak S, Moreau D, Bard F (2013) ScreenSifter: analysis and visualization of RNAi screening data. BMC Bioinf 14:290","journal-title":"BMC Bioinf"},{"key":"5127_CR26","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00432-008-0536-6","volume":"135","author":"E Ruckh\u00e4berle","year":"2009","unstructured":"Ruckh\u00e4berle E et al (2009) Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol 135:1005\u20131013","journal-title":"J Cancer Res Clin Oncol"},{"key":"5127_CR27","doi-asserted-by":"crossref","first-page":"41172","DOI":"10.18632\/oncotarget.9226","volume":"7","author":"J Fleurence","year":"2016","unstructured":"Fleurence J et al (2016) Targeting and killing glioblastoma with monoclonal antibody to O- acetyl GD2 ganglioside. Oncotarget 7:41172\u201341185","journal-title":"Oncotarget"},{"key":"5127_CR28","doi-asserted-by":"crossref","first-page":"791551","DOI":"10.3389\/fimmu.2021.791551","volume":"12","author":"JY Cheng","year":"2021","unstructured":"Cheng JY et al (2021) O-Acetyl-GD2 as a therapeutic target for breast cancer stem cells. Front Immunol 12:791551","journal-title":"Front Immunol"},{"key":"5127_CR29","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.20020960","volume":"196","author":"F Malisan","year":"2002","unstructured":"Malisan F et al (2002) Acetylation suppresses the proapoptotic activity of GD3 ganglioside. J Exp Med 196:1535\u20131541","journal-title":"J Exp Med"},{"key":"5127_CR30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/glycob\/cwr106","volume":"22","author":"C Mandal","year":"2012","unstructured":"Mandal C, Mandal C, Chandra S, Schauer R, Mandal C (2012) Regulation of O- acetylation of sialic acids by sialate-O-acetyltransferase and sialate-O-acetylesterase activities in childhood acute lymphoblastic leukemia. Glycobiology 22:70\u201383","journal-title":"Glycobiology"},{"key":"5127_CR31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/glycob\/cwq153","volume":"21","author":"S Arming","year":"2011","unstructured":"Arming S et al (2011) The human Cas1 protein: a sialic acid-specific O-acetyltransferase? Glycobiology 21:553\u2013564","journal-title":"Glycobiology"},{"key":"5127_CR32","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1038\/ncomms8673","volume":"6","author":"A-MT Baumann","year":"2015","unstructured":"Baumann A-MT et al (2015) 9-O-Acetylation of sialic acids is catalysed by CASD1 via a covalent acetyl- enzyme intermediate. Nat Commun 6:7673","journal-title":"Nat Commun"},{"key":"5127_CR33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/glycob\/cwy110","volume":"29","author":"VS Mahajan","year":"2019","unstructured":"Mahajan VS, Alsufyani F, Mattoo H, Rosenberg I, Pillai S (2019) Alterations in sialic- acid O- acetylation glycoforms during murine erythrocyte development. Glycobiology 29:222\u2013228","journal-title":"Glycobiology"},{"key":"5127_CR34","doi-asserted-by":"crossref","first-page":"109980","DOI":"10.1016\/j.cellsig.2021.109980","volume":"83","author":"A Gomez-Larrauri","year":"2021","unstructured":"Gomez-Larrauri A, Ouro A, Trueba M, Gomez-Mu\u00f1oz A (2021) Regulation of cell growth, survival and migration by ceramide 1-phosphate - implications in lung cancer progression and inflammation. Cell Signal 83:109980","journal-title":"Cell Signal"},{"key":"5127_CR35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bcp.2015.12.009","volume":"102","author":"I-G Rivera","year":"2016","unstructured":"Rivera I-G et al (2016) Ceramide 1-phosphate regulates cell migration and invasion of human pancreatic cancer cells. Biochem Pharmacol 102:107\u2013119","journal-title":"Biochem Pharmacol"},{"key":"5127_CR36","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.1158\/0008-5472.CAN-14-1292","volume":"74","author":"AW Payne","year":"2014","unstructured":"Payne AW, Pant DK, Pan T, Chodosh LA (2014) Ceramide kinase promotes tumor cell survival and mammary tumor recurrence. Cancer Res 74:6352\u20136363","journal-title":"Cancer Res"},{"key":"5127_CR37","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/neuonc\/noab300","volume":"24","author":"E de Billy","year":"2022","unstructured":"de Billy E et al (2022) Dual IGF1R\/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro-Oncol 24:1150\u20131163","journal-title":"Neuro-Oncol"},{"key":"5127_CR38","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG et al (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603:934\u2013941","journal-title":"Nature"},{"key":"5127_CR39","doi-asserted-by":"crossref","first-page":"e63359","DOI":"10.1371\/journal.pone.0063359","volume":"8","author":"M Ahmed","year":"2013","unstructured":"Ahmed M, Goldgur Y, Hu J, Guo H-F, Cheung N-KV (2013) In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. PLoS ONE 8:e63359","journal-title":"PLoS ONE"},{"issue":"4","key":"5127_CR40","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1124\/mol.108.048652","volume":"74","author":"C Graf","year":"2008","unstructured":"Graf C, Klumpp M, Habig M, Rovina P, Billich A, Baumruker T, Oberhauser B, Bornancin F (2008) Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol Pharmacol 74(4):925\u2013932. https:\/\/doi.org\/10.1124\/mol.108.048652","journal-title":"Mol Pharmacol"},{"key":"5127_CR41","doi-asserted-by":"crossref","first-page":"1817653","DOI":"10.1080\/2162402X.2020.1817653","volume":"9","author":"RJE van den Bijgaart","year":"2020","unstructured":"van den Bijgaart RJE et al (2020) Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model. Oncoimmunology 9:1817653","journal-title":"Oncoimmunology"},{"key":"5127_CR42","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1074\/jbc.RA118.002763","volume":"294","author":"RJE van den Bijgaart","year":"2019","unstructured":"van den Bijgaart RJE et al (2019) Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2. J Biol Chem 294:4437\u20134449","journal-title":"J Biol Chem"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05127-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-024-05127-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05127-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T19:04:26Z","timestamp":1743707066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-024-05127-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["5127"],"URL":"https:\/\/doi.org\/10.1007\/s11010-024-05127-5","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]},"assertion":[{"value":"10 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}